ThinPrep® Imaging System
The ThinPrep Imaging System was approved for use by the Food and Drug Administration (FDA) in 2003 to assist in primary cervical cancer screening for cancerous and pre-cancerous cells. Pathology Consultants has been using this innovative screening system since 2004.
ThinPrep Imaging is the first system to provide Dual Review™ whereby both the Imager and Cytotechnologist review every slide. It is also the first system that scans every cell and cell cluster and identifies areas of interest for further review by the Cytotechnologist, which allows the Cytotechnologist to better focus his or her interpretive skills on these defined areas. Since its introduction in 2003, a growing number of laboratories have adopted the ThinPrep Imaging System.
The ThinPrep Imaging System is designed to reduce false negative test results and human error. In addition, the combination of the ThinPrep Pap Test and the ThinPrep Imaging System provides a more accurate diagnosis. The process achieves a higher level of certainty in cervical screening and improves diagnostic capability for greater accuracy. This dual screening approach improves the specificity of HSIL diagnoses, while not losing sensitivity for LSIL, HSIL or other diagnoses, while further reducing the rate of false negatives (39% reduction in false negatives).